Literature DB >> 26588089

Reversibility of Stricturing Crohn's Disease-Fact or Fiction?

Dominik Bettenworth1, Florian Rieder.   

Abstract

Intestinal fibrosis is a common feature of Crohn's disease and may appear as a stricture, stenosis, or intestinal obstruction. Fibrostenosing Crohn's disease leads to a significantly impaired quality of life in affected patients and constitutes a challenging treatment situation. In the absence of specific medical antifibrotic treatment options, endoscopic or surgical therapy approaches with their potential harmful side effects are frequently used. However, our understanding of mechanisms of fibrogenesis in general and specifically intestinal fibrosis has emerged. Progression of fibrosis in the liver, lung, or skin can be halted or even reversed, and possible treatment targets have been identified. In face of this observation and given the fact that fibrotic alterations in various organs of the human body share distinct core characteristics, this article aims to address whether reversibility of intestinal fibrosis may be conceivable and to highlight promising research avenues and therapies.

Entities:  

Mesh:

Year:  2016        PMID: 26588089      PMCID: PMC4679647          DOI: 10.1097/MIB.0000000000000598

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  92 in total

1.  Indications for surgery in Crohn's disease: analysis of 500 cases.

Authors:  R G Farmer; W A Hawk; R B Turnbull
Journal:  Gastroenterology       Date:  1976-08       Impact factor: 22.682

2.  Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.

Authors:  Michael J P Arthur
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

3.  Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.

Authors:  M Hesse; M Modolell; A C La Flamme; M Schito; J M Fuentes; A W Cheever; E J Pearce; T A Wynn
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

4.  Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.

Authors:  Javier Díez; Ramón Querejeta; Begoña López; Arantxa González; Mariano Larman; José L Martínez Ubago
Journal:  Circulation       Date:  2002-05-28       Impact factor: 29.690

5.  Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.

Authors:  Y O Kweon; Z D Goodman; J L Dienstag; E R Schiff; N A Brown; E Burchardt; R Schoonhoven; D A Brenner; M W Fried; E Burkhardt
Journal:  J Hepatol       Date:  2001-12       Impact factor: 25.083

6.  Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells.

Authors:  B Saile; N Matthes; T Knittel; G Ramadori
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

7.  Preoperative characteristics and postoperative behavior of bowel wall on risk of recurrence after conservative surgery in Crohn's disease: a prospective study.

Authors:  G Maconi; G M Sampietro; M Cristaldi; P G Danelli; A Russo; G Bianchi Porro; A M Taschieri
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

8.  Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin.

Authors:  C M Gelbmann; S Mestermann; V Gross; M Köllinger; J Schölmerich; W Falk
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 9.  Hepatic stellate cell behavior during resolution of liver injury.

Authors:  J P Iredale
Journal:  Semin Liver Dis       Date:  2001-08       Impact factor: 6.115

10.  Connective tissue changes in ileal Crohn's disease: relationship to disease phenotype and ulcer-associated cell lineage.

Authors:  N R Borley; N J Mortensen; M G Kettlewell; B D George; D P Jewell; B F Warren
Journal:  Dis Colon Rectum       Date:  2001-03       Impact factor: 4.585

View more
  16 in total

Review 1.  Intestinal fibrosis: ready to be reversed.

Authors:  Giovanni Latella; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

2.  IL-17A Promotes Initiation and Development of Intestinal Fibrosis Through EMT.

Authors:  Hui-Jing Zhang; Yi-Ning Zhang; Huan Zhou; Lin Guan; Yue Li; Ming-Jun Sun
Journal:  Dig Dis Sci       Date:  2018-08-10       Impact factor: 3.199

3.  Endoplasmic Reticulum Stress in Subepithelial Myofibroblasts Increases the TGF-β1 Activity That Regulates Fibrosis in Crohn's Disease.

Authors:  Chao Li; John R Grider; Karnam S Murthy; Jaime Bohl; Emily Rivet; Nicole Wieghard; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

Review 4.  The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease.

Authors:  Michael Scharl; Ramona S Bruckner; Gerhard Rogler
Journal:  United European Gastroenterol J       Date:  2016-02-19       Impact factor: 4.623

Review 5.  Strictureplasty in Complex Crohn's Disease: Beyond the Basics.

Authors:  Scott A Strong
Journal:  Clin Colon Rectal Surg       Date:  2019-07-12

Review 6.  Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.

Authors:  Florian Rieder; Claudio Fiocchi; Gerhard Rogler
Journal:  Gastroenterology       Date:  2016-10-05       Impact factor: 22.682

7.  Paediatric Ulcerative Colitis Is a Fibrotic Disease and Is Linked with Chronicity of Inflammation.

Authors:  Ilyssa O Gordon; Suha Abushamma; Jacob A Kurowski; Stefan D Holubar; Lei Kou; Ruishen Lyu; Florian Rieder
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

8.  Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn's Disease.

Authors:  Mathilde Wagner; Huaibin Mabel Ko; Manjil Chatterji; Cecilia Besa; Joana Torres; Xiaofei Zhang; Hinaben Panchal; Stefanie Hectors; Judy Cho; Jean-Frederic Colombel; Noam Harpaz; Bachir Taouli
Journal:  J Crohns Colitis       Date:  2018-05-25       Impact factor: 9.071

9.  Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.

Authors:  Jun Bon Koo; Myeong-Ok Nam; Younshin Jung; Jongman Yoo; Duk Hwan Kim; Gwangil Kim; Sung Jae Shin; Kee Myung Lee; Ki Baik Hahm; Jong Woo Kim; Sung Pyo Hong; Kwang Jae Lee; Jun Hwan Yoo
Journal:  BMC Gastroenterol       Date:  2017-06-07       Impact factor: 3.067

Review 10.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.